Globus Medical Inc's stock surged by 11.66% as it reached a 52-week high, reflecting strong investor interest despite a slight decline in the broader market, with the Nasdaq-100 down 0.33% and the S&P 500 down 0.11%.
This increase is attributed to the company's announcement of projected Q4 2025 sales of approximately $823.2 million, representing a 25.2% year-over-year growth, significantly exceeding analysts' expectations. The anticipated full-year sales of $2.936 billion for 2025, a 16.5% increase from the previous year, highlights the successful integration of the Nevro acquisition and strong market demand in the spine sector.
The optimistic financial outlook, including projected earnings per share for 2026 between $4.30 and $4.40, reflects management's confidence in future growth. This positive sentiment among investors suggests that Globus Medical is well-positioned for continued success in the medical device market.
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 91.830
Low
87.00
Averages
101.00
High
114.00
Current: 91.830
Low
87.00
Averages
101.00
High
114.00
TD Cowen
initiated
$110
2026-01-26
New
Reason
TD Cowen
Price Target
$110
AI Analysis
2026-01-26
New
initiated
Reason
TD Cowen initiated coverage of Globus Medical with a Buy rating and $110 price target. The stock has overcome a lot of negative sentiment, and while many investors now appreciate the long-tailed earnings power story, there is still room for outperformance, the analyst tells investors in a research note. Enabling Tech/Intenational/Nevro have wood-to-chop, but the firm is confident Globus Medical can affect change, resulting in the potential for out-year, DD top-line growth and multiple expansion, TD Cowen added.
Canaccord
Buy
maintain
$105 -> $112
2026-01-09
Reason
Canaccord
Price Target
$105 -> $112
2026-01-09
maintain
Buy
Reason
Canaccord raised the firm's price target on Globus Medical to $112 from $105 and keeps a Buy rating on the shares. The firm updatedits model to reflect its Q4 preliminary results while noting Nevro preliminary Q4/25 implied revenue was significantly above the firm's $88.8M estimate, coming in at $99.9M.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMED
Unlock Now
Piper Sandler
Matt O'Brien
Overweight
maintain
$90 -> $115
2026-01-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$90 -> $115
2026-01-08
maintain
Overweight
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical to $115 from $90 and keeps an Overweight rating on the shares. The firm notes the company preannounced Q4 revenue of $823.2M, which comes in well above the Street's $778.5M estimate. While the company did not specifically break out Enabling Technology revenue, it did disclose "best quarterly revenue to date" which is a clear positive and, although they are not completely out of the woods yet, signals that things are starting to pick back up again, Piper argues.
Canaccord
Caitlin Cronin
Buy
upgrade
$90 -> $105
2025-12-17
Reason
Canaccord
Caitlin Cronin
Price Target
$90 -> $105
2025-12-17
upgrade
Buy
Reason
Canaccord analyst Caitlin Cronin raised the firm's price target on Globus Medical to $105 from $90 and keeps a Buy rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
